MAGE

Anocca Secures GMP Manufacturing License To Push Novel KRAS TCR-T Cell Therapies Into Clinical Development

Retrieved on: 
Thursday, January 4, 2024

The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises2 of precision targeted cell therapies for different cancers and covering diverse patient populations.

Key Points: 
  • The manufacturing license paves the way for Anocca’s near-term path to the clinic and long-term strategy to advance franchises2 of precision targeted cell therapies for different cancers and covering diverse patient populations.
  • Anocca has built validated asset franchises against valuable cancer targets including KRAS, PRAME and MAGE, with more than 40 preclinical assets in the pipeline.
  • Anocca will initiate its first clinical program in hard-to-treat solid tumour indications with TCR-T therapies across multiple KRAS mutation forms and patient segments.
  • 1 TCR-T therapies: T cell receptor-engineered T cell therapies – a type of cell therapy that uses the natural targeting ability of T cells to identify and eradicate diseased cells like cancer.

Replay and its engineered NK cell therapy company Syena announce exclusive licensing agreement with National Institutes of Health for TCRs targeting cancer neoantigens

Retrieved on: 
Monday, December 18, 2023

These will be developed by Replay’s oncology-focused product company, Syena, to expand its pipeline of engineered T-Cell Receptor-Natural Killer (TCR-NK) cell therapies.

Key Points: 
  • These will be developed by Replay’s oncology-focused product company, Syena, to expand its pipeline of engineered T-Cell Receptor-Natural Killer (TCR-NK) cell therapies.
  • The TCRs, targeting validated cancer neoantigens KRAS, p53, HPV16 and MAGE, were discovered by Steven Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NIH National Cancer Institute’s (NCI) Center for Cancer Research and a pioneer of immunotherapies and gene therapies for advanced cancers.
  • Preclinical development of the new TCR-NK programs will advance alongside the clinical development of Syena’s lead engineered TCR-NK cell therapy candidate targeting NY-ESO-1, and the PRAME program announced today.
  • Adrian Woolfson, Executive Chairman, President, and Co-Founder of Replay, said: “The TCRs licensed from NIH address several cancer neoantigens of medical importance and will significantly expand our first-in-class, engineered TCR-NK therapy operations.

PDC*line Pharma Completes Enrolment of Four Cohorts of Patients in PDC-LUNG-101 Phase I/II Clinical Trial

Retrieved on: 
Wednesday, December 6, 2023

The objectives of the phase I/II trial (PDC-LUNG-101) were to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.

Key Points: 
  • The objectives of the phase I/II trial (PDC-LUNG-101) were to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate PDC*lung01, associated or not with anti-PD-1 treatment in NSCLC patients.
  • The trial was conducted at 17 clinical sites in France, Belgium, Germany, the Netherlands and Poland.
  • “We are pleased to have achieved full patient enrolment in the PDC-LUNG-101 clinical trial, a key step in the product’s clinical development and another important milestone for PDC*line Pharma.
  • “I would like to extend my gratitude to the investigators and patients across the five countries included in our clinical trial.

Enjoy Driving: Dongfeng Passenger Vehicles Comes for Dreams

Retrieved on: 
Wednesday, September 13, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230912433854/en/
    In addition, the popular series products of Dongfeng Passenger Vehicles, the "SHINE FAMILY" full of youth, vitality and passion, are sweeping the world.
  • As another masterpiece of Dongfeng Passenger Vehicles, HUGE has collected the design inspiration of "Wind".
  • Adhering to the brand mission of "DRIVE YOUR DREAMS", Dongfeng Passenger Vehicles has continuously met customers' demand for vehicles with iterative evolution.
  • With the arrival of the era of Dongfeng Smart Power, Dongfeng pure electric brands NANO and eπ will soon join the family of Dongfeng Passenger Vehicles and have zero-distance contact with users around the world.

Newly Engineered Versions of Bacterial Enzyme Reveal How Antibiotics Could Be More Potent

Retrieved on: 
Wednesday, August 30, 2023

NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Modern medicine depends on antibiotics to treat infections by disabling targets inside bacterial cells.

Key Points: 
  • NEW YORK, Aug. 30, 2023 /PRNewswire/ -- Modern medicine depends on antibiotics to treat infections by disabling targets inside bacterial cells.
  • Once inside these cells, antibiotics bind to certain sites on specific enzyme targets to stop bacterial growth.
  • Researchers have for decades studied resistant mutants in hopes that related mechanisms would guide the design of new treatments to overcome resistance.
  • Not only does the antibiotic prevent these mutants from growing, it nearly obliterates the mutant bacterial populations.

HTC Global Services announces the launch of HTCNXT, an Enterprise AI Solutions division

Retrieved on: 
Monday, August 21, 2023

TROY, Mich., Aug. 21, 2023 /PRNewswire/ -- HTC Global Services, a leading provider of technology services, today announced the launch of HTCNXT.

Key Points: 
  • TROY, Mich., Aug. 21, 2023 /PRNewswire/ -- HTC Global Services, a leading provider of technology services, today announced the launch of HTCNXT.
  • Created as an Enterprise AI solutions division, HTCNXT aims to elevate shared human experiences with AI.
  • The President and CEO of HTC Global Services, Madhava Reddy, said, "We are building on HTC Global Services' over thirty years of expertise in technology to power HTCNXT in delivering AI-led solutions.
  • HTCNXT harnesses over 20 contextually relevant Enterprise AI solutions for various sectors, including Retail, Insurance, Travel, and Healthcare.

Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study

Retrieved on: 
Tuesday, June 13, 2023

HELSINKI, Finland and EVRY, France, June 13, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study.

Key Points: 
  • HELSINKI, Finland and EVRY, France, June 13, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study.
  • The collaboration with Texcell will provide insights on PeptiCRAd-1’s ability to modulate immune responses and the mechanism of action of VALO-D102.
  • Dr. Sari Pesonen, CSO at ValoTx, commented, “We are delighted to establish this collaboration with Texcell.
  • This collaboration is a step forward for both of our companies, for the medical industry and for cancer patients.”

Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology

Retrieved on: 
Tuesday, May 23, 2023

No other oncolytic virus therapy delivers tumor targets in this simple but effective and adaptable way.

Key Points: 
  • No other oncolytic virus therapy delivers tumor targets in this simple but effective and adaptable way.
  • The first patient has been administered with PeptiCRAd-1 successfully, without any initial safety concerns and the Safety Data Committee has concluded that the study can continue enrolment.
  • This is a truly innovative immuno-therapy approach which has shown great promise in the pre-clinical setting.
  • We hope to be able to translate this to positive clinical outcomes for patients.”
    “FOR PATIENTS” section on valotx.com for more information!

2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress

Retrieved on: 
Thursday, March 16, 2023

(Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2022.
  • We reported Abecma-related collaborative arrangement revenue of $8.7 million for the fourth quarter of 2022 and collaborative arrangement revenue net of share of collaboration loss of $3.1 million for the year.
  • At the end of February 2023, 2seventy bio raised approximately $117 million in net proceeds through a public equity offering.
  • 2seventy bio ended 2022 with cash, cash equivalents and marketable securities of $267.7 million.

Medigene Receives $3 Million Milestone Payment from 2seventy bio

Retrieved on: 
Wednesday, January 18, 2023

This payment follows the strategic alliance between 2seventy bio (Nasdaq: TSVT), and JW Therapeutics (HKEX: 2126), with the initial focus on the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform.

Key Points: 
  • This payment follows the strategic alliance between 2seventy bio (Nasdaq: TSVT), and JW Therapeutics (HKEX: 2126), with the initial focus on the development of 2seventy bio’s MAGE-A4 program which employs a highly potent TCR discovered in collaboration with Medigene’s proprietary end-to-end technology platform.
  • 2seventy bio (Nasdaq: TSVT) recently announced the initiation of a strategic partnership with JW Therapeutics (HKEX: 2126) with an initial focus of the collaboration being the development of 2seventy bio’s MAGE-A4 cell therapy in mainland China, Hong Kong, and Macao.
  • “We are delighted that Medigene’s partnership with 2seventy bio, has led to the progress of cell therapies in China through 2seventy bio’s strategic alliance with JW Therapeutics,” said Dr. Selwyn Ho, Chief Executive Officer of Medigene.
  • “This alliance, and recent milestone payment to Medigene, further validate our end-to-end technology platform and its potential to deliver differentiated, best-in-class TCRs.